These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11491389)

  • 21. Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
    Woon ST; Baguley BC; Palmer BD; Fraser JD; Ching LM
    Oncol Res; 2002; 13(2):95-101. PubMed ID: 12392157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.
    Zhou S; Feng X; Kestell P; Paxton JW; Baguley BC; Chan E
    Eur J Pharm Sci; 2005 Apr; 24(5):513-24. PubMed ID: 15784341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination.
    Kestell P; Rewcastle GW; Baguley BC
    Xenobiotica; 1994 Jul; 24(7):635-47. PubMed ID: 7975728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
    Zhou S; Feng X; Kestell P; Baguley BC; Paxton JW
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 809(1):87-97. PubMed ID: 15282097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
    Zhou S; Kestell P; Baguley BC; Paxton JW
    Biochem Pharmacol; 2003 Jan; 65(1):109-20. PubMed ID: 12473385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
    Wang LC; Reddy CB; Baguley BC; Kestell P; Sutherland R; Ching LM
    Biochem Pharmacol; 2004 Mar; 67(5):937-45. PubMed ID: 15104247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
    Baguley BC; Zhuang L; Kestell P
    Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(2):343-8. PubMed ID: 11417880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
    Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
    Miners JO; Valente L; Lillywhite KJ; Mackenzie PI; Burchell B; Baguley BC; Kestell P
    Cancer Res; 1997 Jan; 57(2):284-9. PubMed ID: 9000569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Philpott M; Baguley BC; Ching LM
    Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
    Zhou S; Paxton JW; Tingle MD; Kestell P
    J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(2):359-63. PubMed ID: 11417882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of the site of glucuronidation in an N-(3,5-dichlorophenyl)succinimide metabolite by electrospray ionization tandem mass spectrometry following derivatization to picolinyl esters.
    Cui D; Harvison PJ
    Rapid Commun Mass Spectrom; 2000; 14(21):1985-90. PubMed ID: 11085408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
    Jameson MB; Thompson PI; Baguley BC; Evans BD; Harvey VJ; Porter DJ; McCrystal MR; Small M; Bellenger K; Gumbrell L; Halbert GW; Kestell P;
    Br J Cancer; 2003 Jun; 88(12):1844-50. PubMed ID: 12799625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the reactivity of acyl glucuronides--V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and beta-glucuronidase.
    Dickinson RG; King AR
    Biochem Pharmacol; 1993 Oct; 46(7):1175-82. PubMed ID: 8216368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.